What’s New in ISO 10993-1:2025 for Medical Devices

What’s New in ISO 10993-1:2025 for Medical Devices

Introduction

Biocompatibility is a critical requirement for every medical device that comes in contact with the human body. Regulators across the world rely on the ISO 10993 series to evaluate whether a device is safe for patients. In 2025, a revised version of ISO 10993-1 was released, bringing important updates that affect medical device manufacturers, toxicologists and regulatory teams.

For companies preparing devices for global markets, understanding ISO 10993-1:2025 is no longer optional. The new edition places stronger emphasis on risk-based thinking, chemical characterization and the use of existing data instead of unnecessary testing.

In this blog, Accuprec Research Labs Pvt. Ltd. explains what is new in ISO 10993-1:2025, why it matters and how manufacturers can align their biocompatibility strategies with the updated standard.

What Is ISO 10993-1?

ISO 10993-1 is the foundation of the ISO 10993 biocompatibility series. It defines the general principles for biological evaluation of medical devices. Instead of prescribing specific tests for every device, the standard guides manufacturers to:

• Understand device materials and manufacturing processes
• Identify potential biological risks
• Plan a suitable biological evaluation strategy
• Use scientific justification and existing data wherever possible

ISO 10993-1 works together with other parts of the series, such as ISO 10993-17 (toxicological risk assessment) and ISO 10993-18 (chemical characterization).

Why the 2025 Update Is Important

The medical device industry has evolved rapidly in recent years. New materials, complex manufacturing processes and stricter global regulations have made biocompatibility assessment more challenging. Regulators such as the FDA and EU Notified Bodies now expect a deeper scientific rationale rather than a checklist-based testing approach.

ISO 10993-1:2025 addresses these expectations by:

• Strengthening the risk management approach
• Aligning more closely with ISO 14971
• Reducing reliance on animal testing
• Emphasizing chemical and toxicological evaluation

These changes help improve patient safety while also reducing unnecessary time and cost for manufacturers.

Key Changes in ISO 10993-1:2025

1. Stronger Risk-Based Approach

One of the most important updates in ISO 10993-1:2025 is the stronger integration of risk management principles. The standard now clearly links biological evaluation with ISO 14971 risk management activities.

Manufacturers are expected to:

• Identify biological hazards early
• Estimate and evaluate biological risks
• Implement risk control measures
• Evaluate residual risks

Biocompatibility is no longer treated as a standalone activity. Instead, it is part of the overall device risk management lifecycle.

2. Clearer Guidance on Device Categorization

ISO 10993-1:2025 provides clearer explanations on how to categorize devices based on:

• Nature of body contact (surface, external communicating, implant)
• Duration of contact (limited, prolonged, permanent)

While these categories existed earlier, the 2025 version improves clarity and reduces misinterpretation. This helps manufacturers select relevant biological endpoints more accurately.

3. Increased Focus on Chemical Characterization

The 2025 update places significant importance on chemical characterization as the starting point of biocompatibility evaluation. Instead of directly performing biological tests, manufacturers are encouraged to:

• Identify extractables and leachables
• Understand material composition
• Evaluate potential patient exposure

This approach supports the use of ISO 10993-18 and ISO 10993-17 to scientifically assess risk before considering in vivo testing.

4. Reduced Dependence on Animal Testing

ISO 10993-1:2025 strongly supports the 3Rs principle (Replace, Reduce, Refine animal testing). The standard encourages:

• Use of existing clinical data
• Literature reviews
• In vitro and in silico methods
• Toxicological risk assessment

Animal testing should only be conducted when scientifically justified and when no suitable alternatives are available.

5. Better Use of Existing Data

The updated standard emphasizes the value of existing data, including:

• Previous biocompatibility studies
• Clinical experience
• Post-market surveillance data
• Supplier material data

Manufacturers must critically evaluate data relevance and quality, but unnecessary repetition of tests is discouraged.

6. Clear Expectations for Biological Evaluation Plans (BEP)

ISO 10993-1:2025 provides improved guidance on Biological Evaluation Plans (BEP). A BEP should:

• Define the evaluation strategy
• Justify selected tests or exclusions
• Reference applicable standards
• Be aligned with risk management

Regulators now expect the BEP to be a living document that evolves with design changes.

7. Stronger Alignment with Regulatory Expectations

The 2025 revision aligns more closely with regulatory expectations from:

• US FDA
• EU MDR
• Other global regulatory bodies

This alignment helps manufacturers prepare biocompatibility documentation that is more likely to be accepted during regulatory review.

Impact on Medical Device Manufacturers

ISO 10993-1:2025 changes how manufacturers approach biocompatibility. Instead of a test-driven process, companies must adopt a science-driven strategy.

Key impacts include:

• Early involvement of toxicologists
• More detailed documentation
• Better cross-functional collaboration
• Improved regulatory confidence

While this may require more planning upfront, it often reduces delays and costly rework later.

How Accuprec Research Labs Supports ISO 10993-1:2025 Compliance

Accuprec Research Labs Pvt. Ltd. supports medical device companies through every stage of biocompatibility evaluation. Our expertise includes:

• Risk-based biocompatibility strategy development
• Chemical characterization studies
• Toxicological risk assessment
• BEP and BER preparation
• Regulatory support for global submissions

Our team stays updated with the latest standards, including ISO 10993-1:2025, to ensure accurate, compliant and efficient evaluations.

Conclusion

ISO 10993-1:2025 represents a major step forward in biocompatibility evaluation for medical devices. By focusing on risk management, chemical characterization and scientific justification, the new standard improves patient safety while reducing unnecessary testing.

Manufacturers who understand and adopt these changes early will be better positioned for regulatory success. With the right expertise and planning, compliance with ISO 10993-1:2025 can become a strategic advantage rather than a regulatory burden.

Accuprec Research Labs Pvt. Ltd. is committed to helping medical device companies navigate these changes with confidence and clarity.